Obesity and body weight control

February 2, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Pyridoxamine and Sitagliptin (PAS) inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 2/February/2018, 11.58 pm

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator […]
February 1, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM:  Triiodothronine (T3), a thyroid hormone, decreases CADM1 and its downstream target genes that promote glucose-induced insulin secretion, improves insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 2/February/2018, 12.10 am

Introduction: What they say A study from the Max Delbrück Center for Molecular Medicine, Berlin, Germany shows that “Regulation of body weight and energy homeostasis by […]
January 29, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Pantoprazole (brand name: Protonix), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 29/January/2018, 11.18 pm

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]
January 28, 2018

Molecular therapy for body weight control, energy homeostasis and TIIDM: Omeprazole(brand name: Prelosec, Losec), a drug used in the treatment of stomach and duodenal ulcers,  increases REV-ERB and its down stream target genes, inhibits lipid accumulation, improves dyslipidemia and insulin sensitivity, increases energy utilization, promotes weight loss and protects from diet-induced obesity and TIIDM via up regulation of its target gene, 28/January/2018, 11.08 pm

Introduction: What they say A study from the Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida 33458, USA shows that “Regulation of circadian behaviour […]